Last 12 months
Inside the activity.
1 purchase rows · 10 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 1 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 10 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 28, 2025 Filed May 29, 2025 16:15 UTC |
Ackerman JohnDirector
|
SaleClass A Common Stock | 50,305 | $20.16 | $1,014,148.80 |
DisclosureSEC source: 0000950170-25-078971 · ownership.xml · nonDerivative · entry 4 Ackerman John · CIK 0002037898 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Cardinal Equity Fund, L.P. Disclosed balance after: 149,794 F1 · kind: Represents shares of Class A common stock, par value $0.001 per share, of Guardian Pharmacy Services, Inc. (the "Issuer"), sold pursuant to the Underwriting Agreement, dated May 22, 2025, by and among the Issuer, the selling stockholders party thereto and Raymond James & Associates, Inc., as representative of the several underwriters named therein. Read SEC document |
| May 28, 2025 Filed May 29, 2025 16:15 UTC |
Ackerman JohnDirector
|
SaleClass A Common Stock | 150,998 | $20.16 | $3,044,119.68 |
DisclosureSEC source: 0000950170-25-078971 · ownership.xml · nonDerivative · entry 3 Ackerman John · CIK 0002037898 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Pharmacy Investors, LLC Disclosed balance after: 449,624 F1 · kind: Represents shares of Class A common stock, par value $0.001 per share, of Guardian Pharmacy Services, Inc. (the "Issuer"), sold pursuant to the Underwriting Agreement, dated May 22, 2025, by and among the Issuer, the selling stockholders party thereto and Raymond James & Associates, Inc., as representative of the several underwriters named therein. Read SEC document |
| May 28, 2025 Filed May 29, 2025 16:15 UTC |
Salentine Thomas J JrDirector · 10% owner
|
SaleClass A Common Stock | 651,454 | $20.16 | $13,133,312.64 |
DisclosureSEC source: 0000950170-25-078972 · ownership.xml · nonDerivative · entry 2 Salentine Thomas J Jr · CIK 0002037899 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Bindley Capital Partners I, LLC Disclosed balance after: 1,939,817 F1 · kind: Represents shares of Class A common stock, par value $0.001 per share, of Guardian Pharmacy Services, Inc. (the "Issuer"), sold pursuant to the Underwriting Agreement, dated May 22, 2025, by and among the Issuer, the selling stockholders party thereto and Raymond James & Associates, Inc., as representative of the several underwriters named therein. Read SEC document |
| May 28, 2025 Filed Sep 30, 2025 16:10 UTC |
Cardinal Equity Fund, L.P.Member of 10% owner group
|
SaleClass A Common Stock | 50,305 | $20.16 | $1,014,148.80 |
DisclosureSEC source: 0001193125-25-225032 · ownership.xml · nonDerivative · entry 2 Cardinal Equity Fund, L.P. · CIK 0001432819 · Member of 10% owner group 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,794 F1 · kind: Represents shares of Guardian Pharmacy Services, Inc.'s (the "Issuer") Class A common stock sold pursuant to the Underwriting Agreement, dated May 22, 2025, by and among the Issuer, the selling stockholders party thereto and Raymond James & Associates, Inc., as representative of the several underwriters named therein. Read SEC document |
| May 28, 2025 Filed Sep 30, 2025 20:10 UTC |
Pharmacy Investors, LLCMember of 10% owner group
|
SaleClass A Common Stock | 150,998 | $20.16 | $3,044,119.68 |
DisclosureSEC source: 0001193125-25-225027 · ownership.xml · nonDerivative · entry 2 Pharmacy Investors, LLC · CIK 0002038519 · Member of 10% owner group 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 449,624 F1 · kind: Represents shares of Guardian Pharmacy Services, Inc.'s (the "Issuer") Class A common stock sold pursuant to the Underwriting Agreement, dated May 22, 2025, by and among the Issuer, the selling stockholders party thereto and Raymond James & Associates, Inc., as representative of the several underwriters named therein. Read SEC document |
| May 27, 2025 Filed May 29, 2025 16:15 UTC |
BINDLEY WILLIAM EDirector · 10% owner
|
SaleClass A Common Stock | 3,508,905 | $20.16 | $70,739,524.80 |
DisclosureSEC source: 0000950170-25-078973 · ownership.xml · nonDerivative · entry 1 BINDLEY WILLIAM E · CIK 0000903539 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Bindley Capital Partners I, LLC Disclosed balance after: 2,591,271 F1 · kind: Represents shares of Class A common stock, par value $0.001 per share, of Guardian Pharmacy Services, Inc. (the "Issuer"), sold pursuant to the Underwriting Agreement, dated May 22, 2025, by and among the Issuer, the selling stockholders party thereto and Raymond James & Associates, Inc., as representative of the several underwriters named therein. Read SEC document |
| May 27, 2025 Filed May 29, 2025 16:15 UTC |
Forbes KendallSee Remarks
|
SaleClass A Common Stock | 350,058 | $20.16 | $7,057,169.28 |
DisclosureSEC source: 0000950170-25-078968 · ownership.xml · nonDerivative · entry 1 Forbes Kendall · CIK 0002038507 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 268,897 F1 · kind: Represents shares of Class A common stock, par value $0.001 per share, of Guardian Pharmacy Services, Inc. (the "Issuer"), sold pursuant to the Underwriting Agreement, dated May 22, 2025, by and among the Issuer, the selling stockholders party thereto and Raymond James & Associates, Inc., as representative of the several underwriters named therein. Read SEC document |
| May 27, 2025 Filed May 29, 2025 15:06 UTC |
Bindley Capital Partners I, LLC10% owner
|
SaleClass A Common Stock | 3,508,905 | $20.16 | $70,739,524.80 |
DisclosureSEC source: 0000950170-25-078856 · ownership.xml · nonDerivative · entry 1 Bindley Capital Partners I, LLC · CIK 0002038820 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,591,271 F1 · kind: Represents shares of Class A common stock, par value $0.001 per share, of Guardian Pharmacy Services, Inc. (the "Issuer"), sold pursuant to the Underwriting Agreement, dated May 22, 2025, by and among the Issuer, the selling stockholders party thereto and Raymond James & Associates, Inc., as representative of the several underwriters named therein. Read SEC document |
| May 27, 2025 Filed May 29, 2025 16:15 UTC |
Burke FredDirector · See Remarks
|
SaleClass A Common Stock | 747,102 | $20.16 | $15,061,576.32 |
DisclosureSEC source: 0000950170-25-078969 · ownership.xml · nonDerivative · entry 1 Burke Fred · CIK 0002037972 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 551,724 F1 · kind: Represents shares of Class A common stock, par value $0.001 per share, of Guardian Pharmacy Services, Inc. (the "Issuer"), sold pursuant to the Underwriting Agreement, dated May 22, 2025, by and among the Issuer, the selling stockholders party thereto and Raymond James & Associates, Inc., as representative of the several underwriters named therein. Read SEC document |
| May 27, 2025 Filed May 29, 2025 16:15 UTC |
Morris David KDirector · See Remarks
|
SaleClass A Common Stock | 369,212 | $20.16 | $7,443,313.92 |
DisclosureSEC source: 0000950170-25-078970 · ownership.xml · nonDerivative · entry 1 Morris David K · CIK 0002037977 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 283,042 F1 · kind: Represents shares of Class A common stock, par value $0.001 per share, of Guardian Pharmacy Services, Inc. (the "Issuer"), sold pursuant to the Underwriting Agreement, dated May 22, 2025, by and among the Issuer, the selling stockholders party thereto and Raymond James & Associates, Inc., as representative of the several underwriters named therein. Read SEC document |
| May 27, 2025 Filed May 29, 2025 16:15 UTC |
Ackerman JohnDirector
|
SaleClass A Common Stock | 270,958 | $20.16 | $5,462,513.28 |
DisclosureSEC source: 0000950170-25-078971 · ownership.xml · nonDerivative · entry 2 Ackerman John · CIK 0002037898 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Cardinal Equity Fund, L.P. Disclosed balance after: 200,099 F1 · kind: Represents shares of Class A common stock, par value $0.001 per share, of Guardian Pharmacy Services, Inc. (the "Issuer"), sold pursuant to the Underwriting Agreement, dated May 22, 2025, by and among the Issuer, the selling stockholders party thereto and Raymond James & Associates, Inc., as representative of the several underwriters named therein. Read SEC document |
| May 27, 2025 Filed May 29, 2025 16:15 UTC |
Ackerman JohnDirector
|
SaleClass A Common Stock | 813,318 | $20.16 | $16,396,490.88 |
DisclosureSEC source: 0000950170-25-078971 · ownership.xml · nonDerivative · entry 1 Ackerman John · CIK 0002037898 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Pharmacy Investors, LLC Disclosed balance after: 600,622 F1 · kind: Represents shares of Class A common stock, par value $0.001 per share, of Guardian Pharmacy Services, Inc. (the "Issuer"), sold pursuant to the Underwriting Agreement, dated May 22, 2025, by and among the Issuer, the selling stockholders party thereto and Raymond James & Associates, Inc., as representative of the several underwriters named therein. Read SEC document |
| May 27, 2025 Filed May 29, 2025 16:15 UTC |
Salentine Thomas J JrDirector · 10% owner
|
SaleClass A Common Stock | 3,508,905 | $20.16 | $70,739,524.80 |
DisclosureSEC source: 0000950170-25-078972 · ownership.xml · nonDerivative · entry 1 Salentine Thomas J Jr · CIK 0002037899 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Bindley Capital Partners I, LLC Disclosed balance after: 2,591,271 F1 · kind: Represents shares of Class A common stock, par value $0.001 per share, of Guardian Pharmacy Services, Inc. (the "Issuer"), sold pursuant to the Underwriting Agreement, dated May 22, 2025, by and among the Issuer, the selling stockholders party thereto and Raymond James & Associates, Inc., as representative of the several underwriters named therein. Read SEC document |
| May 27, 2025 Filed Sep 30, 2025 16:10 UTC |
Cardinal Equity Fund, L.P.Member of 10% owner group
|
SaleClass A Common Stock | 270,958 | $20.16 | $5,462,513.28 |
DisclosureSEC source: 0001193125-25-225032 · ownership.xml · nonDerivative · entry 1 Cardinal Equity Fund, L.P. · CIK 0001432819 · Member of 10% owner group 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,099 F1 · kind: Represents shares of Guardian Pharmacy Services, Inc.'s (the "Issuer") Class A common stock sold pursuant to the Underwriting Agreement, dated May 22, 2025, by and among the Issuer, the selling stockholders party thereto and Raymond James & Associates, Inc., as representative of the several underwriters named therein. Read SEC document |
| May 27, 2025 Filed Sep 30, 2025 20:10 UTC |
Pharmacy Investors, LLCMember of 10% owner group
|
SaleClass A Common Stock | 813,318 | $20.16 | $16,396,490.88 |
DisclosureSEC source: 0001193125-25-225027 · ownership.xml · nonDerivative · entry 1 Pharmacy Investors, LLC · CIK 0002038519 · Member of 10% owner group 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600,622 F1 · kind: Represents shares of Guardian Pharmacy Services, Inc.'s (the "Issuer") Class A common stock sold pursuant to the Underwriting Agreement, dated May 22, 2025, by and among the Issuer, the selling stockholders party thereto and Raymond James & Associates, Inc., as representative of the several underwriters named therein. Read SEC document |
| May 09, 2025 Filed May 12, 2025 21:36 UTC |
LEWIS RANDALL JDirector
|
GrantClass A Common Stock | 3,901 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-069500 · ownership.xml · nonDerivative · entry 1 LEWIS RANDALL J · CIK 0001123485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,043 F1 · shares: Represents restricted stock units payable solely in shares of Class A common stock of the Issuer. Read SEC document |
| May 09, 2025 Filed May 12, 2025 21:42 UTC |
COSLER STEVEN DDirector
|
GrantClass A Common Stock | 3,901 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-069513 · ownership.xml · nonDerivative · entry 1 COSLER STEVEN D · CIK 0001187946 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,614 F1 · shares: Represents restricted stock units payable solely in shares of Class A common stock of the Issuer. Read SEC document |
| May 09, 2025 Filed May 12, 2025 21:40 UTC |
Patchett Mary SueDirector
|
GrantClass A Common Stock | 3,901 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-069506 · ownership.xml · nonDerivative · entry 1 Patchett Mary Sue · CIK 0001568874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,043 F1 · shares: Represents restricted stock units payable solely in shares of Class A common stock of the Issuer. Read SEC document |
| March 28, 2025 Filed Apr 1, 2025 16:59 UTC |
BINDLEY WILLIAM EDirector · 10% owner
|
Exercise / conversionClass B Common Stock · Derivative | 6,100,176 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-048679 · ownership.xml · derivative · entry 2 BINDLEY WILLIAM E · CIK 0000903539 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Bindley Capital Partners I, LLC Disclosed balance after: 18,300,526 Underlying: Class A Common Stock · 6,100,176 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Pursuant to Guardian Pharmacy Services, Inc.'s (the "Issuer") Amended and Restated Certificate of Incorporation, the Reporting Person's shares of Class B common stock automatically convert into shares of the Issuer's Class A common stock, on a one-for-one basis, in four substantially equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. F1 · price: Pursuant to Guardian Pharmacy Services, Inc.'s (the "Issuer") Amended and Restated Certificate of Incorporation, the Reporting Person's shares of Class B common stock automatically convert into shares of the Issuer's Class A common stock, on a one-for-one basis, in four substantially equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. F1 · derivative.exercise_date: Pursuant to Guardian Pharmacy Services, Inc.'s (the "Issuer") Amended and Restated Certificate of Incorporation, the Reporting Person's shares of Class B common stock automatically convert into shares of the Issuer's Class A common stock, on a one-for-one basis, in four substantially equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. F1 · derivative.expiration_date: Pursuant to Guardian Pharmacy Services, Inc.'s (the "Issuer") Amended and Restated Certificate of Incorporation, the Reporting Person's shares of Class B common stock automatically convert into shares of the Issuer's Class A common stock, on a one-for-one basis, in four substantially equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. Read SEC document |
| March 28, 2025 Filed Apr 1, 2025 16:59 UTC |
BINDLEY WILLIAM EDirector · 10% owner
|
Exercise / conversionClass A Common Stock | 6,100,176 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-048679 · ownership.xml · nonDerivative · entry 1 BINDLEY WILLIAM E · CIK 0000903539 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Bindley Capital Partners I, LLC Disclosed balance after: 6,100,176 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Pursuant to Guardian Pharmacy Services, Inc.'s (the "Issuer") Amended and Restated Certificate of Incorporation, the Reporting Person's shares of Class B common stock automatically convert into shares of the Issuer's Class A common stock, on a one-for-one basis, in four substantially equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. Read SEC document |
| March 28, 2025 Filed Apr 1, 2025 16:15 UTC |
Forbes KendallSee Remarks
|
Exercise / conversionClass B Common Stock · Derivative | 608,570 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-048530 · ownership.xml · derivative · entry 2 Forbes Kendall · CIK 0002038507 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,825,710 Underlying: Class A Common Stock · 608,570 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Pursuant to Guardian Pharmacy Services, Inc.'s (the "Issuer") Amended and Restated Certificate of Incorporation, the Reporting Person's shares of Class B common stock automatically convert into shares of the Issuer's Class A common stock, on a one-for-one basis, in four substantially equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. F1 · price: Pursuant to Guardian Pharmacy Services, Inc.'s (the "Issuer") Amended and Restated Certificate of Incorporation, the Reporting Person's shares of Class B common stock automatically convert into shares of the Issuer's Class A common stock, on a one-for-one basis, in four substantially equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. F1 · derivative.exercise_date: Pursuant to Guardian Pharmacy Services, Inc.'s (the "Issuer") Amended and Restated Certificate of Incorporation, the Reporting Person's shares of Class B common stock automatically convert into shares of the Issuer's Class A common stock, on a one-for-one basis, in four substantially equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. F1 · derivative.expiration_date: Pursuant to Guardian Pharmacy Services, Inc.'s (the "Issuer") Amended and Restated Certificate of Incorporation, the Reporting Person's shares of Class B common stock automatically convert into shares of the Issuer's Class A common stock, on a one-for-one basis, in four substantially equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. Read SEC document |
| March 28, 2025 Filed Apr 1, 2025 16:15 UTC |
Forbes KendallSee Remarks
|
Exercise / conversionClass A Common Stock | 608,570 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-048530 · ownership.xml · nonDerivative · entry 1 Forbes Kendall · CIK 0002038507 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 618,955 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Pursuant to Guardian Pharmacy Services, Inc.'s (the "Issuer") Amended and Restated Certificate of Incorporation, the Reporting Person's shares of Class B common stock automatically convert into shares of the Issuer's Class A common stock, on a one-for-one basis, in four substantially equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. Read SEC document |
| March 28, 2025 Filed Apr 1, 2025 16:15 UTC |
Burke FredDirector · See Remarks
|
Exercise / conversionClass B Common Stock · Derivative | 1,298,826 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-048526 · ownership.xml · derivative · entry 2 Burke Fred · CIK 0002037972 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,896,477 Underlying: Class A Common Stock · 1,298,826 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Pursuant to Guardian Pharmacy Services, Inc.'s (the "Issuer") Amended and Restated Certificate of Incorporation, the Reporting Person's shares of Class B common stock automatically convert into shares of the Issuer's Class A common stock, on a one-for-one basis, in four substantially equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. F1 · price: Pursuant to Guardian Pharmacy Services, Inc.'s (the "Issuer") Amended and Restated Certificate of Incorporation, the Reporting Person's shares of Class B common stock automatically convert into shares of the Issuer's Class A common stock, on a one-for-one basis, in four substantially equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. F1 · derivative.exercise_date: Pursuant to Guardian Pharmacy Services, Inc.'s (the "Issuer") Amended and Restated Certificate of Incorporation, the Reporting Person's shares of Class B common stock automatically convert into shares of the Issuer's Class A common stock, on a one-for-one basis, in four substantially equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. F1 · derivative.expiration_date: Pursuant to Guardian Pharmacy Services, Inc.'s (the "Issuer") Amended and Restated Certificate of Incorporation, the Reporting Person's shares of Class B common stock automatically convert into shares of the Issuer's Class A common stock, on a one-for-one basis, in four substantially equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. Read SEC document |
| March 28, 2025 Filed Apr 1, 2025 16:15 UTC |
Burke FredDirector · See Remarks
|
Exercise / conversionClass A Common Stock | 1,298,826 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-048526 · ownership.xml · nonDerivative · entry 1 Burke Fred · CIK 0002037972 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,298,826 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Pursuant to Guardian Pharmacy Services, Inc.'s (the "Issuer") Amended and Restated Certificate of Incorporation, the Reporting Person's shares of Class B common stock automatically convert into shares of the Issuer's Class A common stock, on a one-for-one basis, in four substantially equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. Read SEC document |
| March 28, 2025 Filed Apr 1, 2025 16:15 UTC |
Morris David KDirector · See Remarks
|
Exercise / conversionClass B Common Stock · Derivative | 641,869 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-048532 · ownership.xml · derivative · entry 2 Morris David K · CIK 0002037977 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,925,608 Underlying: Class A Common Stock · 641,869 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Pursuant to Guardian Pharmacy Services, Inc.'s (the "Issuer") Amended and Restated Certificate of Incorporation, the Reporting Person's shares of Class B common stock automatically convert into shares of the Issuer's Class A common stock, on a one-for-one basis, in four substantially equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. F1 · price: Pursuant to Guardian Pharmacy Services, Inc.'s (the "Issuer") Amended and Restated Certificate of Incorporation, the Reporting Person's shares of Class B common stock automatically convert into shares of the Issuer's Class A common stock, on a one-for-one basis, in four substantially equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. F1 · derivative.exercise_date: Pursuant to Guardian Pharmacy Services, Inc.'s (the "Issuer") Amended and Restated Certificate of Incorporation, the Reporting Person's shares of Class B common stock automatically convert into shares of the Issuer's Class A common stock, on a one-for-one basis, in four substantially equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. F1 · derivative.expiration_date: Pursuant to Guardian Pharmacy Services, Inc.'s (the "Issuer") Amended and Restated Certificate of Incorporation, the Reporting Person's shares of Class B common stock automatically convert into shares of the Issuer's Class A common stock, on a one-for-one basis, in four substantially equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. Read SEC document |
| March 28, 2025 Filed Apr 1, 2025 16:15 UTC |
Morris David KDirector · See Remarks
|
Exercise / conversionClass A Common Stock | 641,869 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-048532 · ownership.xml · nonDerivative · entry 1 Morris David K · CIK 0002037977 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 652,254 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Pursuant to Guardian Pharmacy Services, Inc.'s (the "Issuer") Amended and Restated Certificate of Incorporation, the Reporting Person's shares of Class B common stock automatically convert into shares of the Issuer's Class A common stock, on a one-for-one basis, in four substantially equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. Read SEC document |
| March 28, 2025 Filed Apr 1, 2025 16:15 UTC |
Ackerman JohnDirector
|
Exercise / conversionClass B Common Stock · Derivative | 471,057 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-048531 · ownership.xml · derivative · entry 4 Ackerman John · CIK 0002037898 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Cardinal Equity Fund, L.P. Disclosed balance after: 1,413,171 Underlying: Class A Common Stock · 471,057 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Pursuant to Guardian Pharmacy Services, Inc.'s (the "Issuer") Amended and Restated Certificate of Incorporation, the Reporting Person's shares of Class B common stock automatically convert into shares of the Issuer's Class A common stock, on a one-for-one basis, in four substantially equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. F1 · price: Pursuant to Guardian Pharmacy Services, Inc.'s (the "Issuer") Amended and Restated Certificate of Incorporation, the Reporting Person's shares of Class B common stock automatically convert into shares of the Issuer's Class A common stock, on a one-for-one basis, in four substantially equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. F1 · derivative.exercise_date: Pursuant to Guardian Pharmacy Services, Inc.'s (the "Issuer") Amended and Restated Certificate of Incorporation, the Reporting Person's shares of Class B common stock automatically convert into shares of the Issuer's Class A common stock, on a one-for-one basis, in four substantially equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. F1 · derivative.expiration_date: Pursuant to Guardian Pharmacy Services, Inc.'s (the "Issuer") Amended and Restated Certificate of Incorporation, the Reporting Person's shares of Class B common stock automatically convert into shares of the Issuer's Class A common stock, on a one-for-one basis, in four substantially equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. Read SEC document |
| March 28, 2025 Filed Apr 1, 2025 16:15 UTC |
Ackerman JohnDirector
|
Exercise / conversionClass B Common Stock · Derivative | 1,413,940 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-048531 · ownership.xml · derivative · entry 3 Ackerman John · CIK 0002037898 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Pharmacy Investors, LLC Disclosed balance after: 4,241,818 Underlying: Class A Common Stock · 1,413,940 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Pursuant to Guardian Pharmacy Services, Inc.'s (the "Issuer") Amended and Restated Certificate of Incorporation, the Reporting Person's shares of Class B common stock automatically convert into shares of the Issuer's Class A common stock, on a one-for-one basis, in four substantially equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. F1 · price: Pursuant to Guardian Pharmacy Services, Inc.'s (the "Issuer") Amended and Restated Certificate of Incorporation, the Reporting Person's shares of Class B common stock automatically convert into shares of the Issuer's Class A common stock, on a one-for-one basis, in four substantially equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. F1 · derivative.exercise_date: Pursuant to Guardian Pharmacy Services, Inc.'s (the "Issuer") Amended and Restated Certificate of Incorporation, the Reporting Person's shares of Class B common stock automatically convert into shares of the Issuer's Class A common stock, on a one-for-one basis, in four substantially equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. F1 · derivative.expiration_date: Pursuant to Guardian Pharmacy Services, Inc.'s (the "Issuer") Amended and Restated Certificate of Incorporation, the Reporting Person's shares of Class B common stock automatically convert into shares of the Issuer's Class A common stock, on a one-for-one basis, in four substantially equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. Read SEC document |
| March 28, 2025 Filed Apr 1, 2025 16:15 UTC |
Ackerman JohnDirector
|
Exercise / conversionClass A Common Stock | 471,057 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-048531 · ownership.xml · nonDerivative · entry 2 Ackerman John · CIK 0002037898 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Cardinal Equity Fund, L.P. Disclosed balance after: 471,057 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Pursuant to Guardian Pharmacy Services, Inc.'s (the "Issuer") Amended and Restated Certificate of Incorporation, the Reporting Person's shares of Class B common stock automatically convert into shares of the Issuer's Class A common stock, on a one-for-one basis, in four substantially equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. Read SEC document |
| March 28, 2025 Filed Apr 1, 2025 16:15 UTC |
Ackerman JohnDirector
|
Exercise / conversionClass A Common Stock | 1,413,940 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-048531 · ownership.xml · nonDerivative · entry 1 Ackerman John · CIK 0002037898 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Pharmacy Investors, LLC Disclosed balance after: 1,413,940 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Pursuant to Guardian Pharmacy Services, Inc.'s (the "Issuer") Amended and Restated Certificate of Incorporation, the Reporting Person's shares of Class B common stock automatically convert into shares of the Issuer's Class A common stock, on a one-for-one basis, in four substantially equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. Read SEC document |
| March 28, 2025 Filed Apr 1, 2025 16:15 UTC |
Salentine Thomas J JrDirector
|
Exercise / conversionClass B Common Stock · Derivative | 6,100,176 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-048528 · ownership.xml · derivative · entry 3 Salentine Thomas J Jr · CIK 0002037899 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Bindley Capital Partners I, LLC Disclosed balance after: 18,300,526 Underlying: Class A Common Stock · 6,100,176 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Pursuant to Guardian Pharmacy Services, Inc.'s (the "Issuer") Amended and Restated Certificate of Incorporation, the Reporting Person's shares of Class B common stock automatically convert into shares of the Issuer's Class A common stock, on a one-for-one basis, in four substantially equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. F1 · price: Pursuant to Guardian Pharmacy Services, Inc.'s (the "Issuer") Amended and Restated Certificate of Incorporation, the Reporting Person's shares of Class B common stock automatically convert into shares of the Issuer's Class A common stock, on a one-for-one basis, in four substantially equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. F1 · derivative.exercise_date: Pursuant to Guardian Pharmacy Services, Inc.'s (the "Issuer") Amended and Restated Certificate of Incorporation, the Reporting Person's shares of Class B common stock automatically convert into shares of the Issuer's Class A common stock, on a one-for-one basis, in four substantially equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. F1 · derivative.expiration_date: Pursuant to Guardian Pharmacy Services, Inc.'s (the "Issuer") Amended and Restated Certificate of Incorporation, the Reporting Person's shares of Class B common stock automatically convert into shares of the Issuer's Class A common stock, on a one-for-one basis, in four substantially equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. Read SEC document |
| March 28, 2025 Filed Apr 1, 2025 16:15 UTC |
Salentine Thomas J JrDirector
|
Exercise / conversionClass A Common Stock | 6,100,176 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-048528 · ownership.xml · nonDerivative · entry 1 Salentine Thomas J Jr · CIK 0002037899 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Bindley Capital Partners I, LLC Disclosed balance after: 6,100,176 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Pursuant to Guardian Pharmacy Services, Inc.'s (the "Issuer") Amended and Restated Certificate of Incorporation, the Reporting Person's shares of Class B common stock automatically convert into shares of the Issuer's Class A common stock, on a one-for-one basis, in four substantially equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 16:15 UTC |
Forbes KendallSee Remarks
|
GrantClass A Common Stock | 10,385 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-016285 · ownership.xml · nonDerivative · entry 1 Forbes Kendall · CIK 0002038507 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,385 F1 · shares: Consists of restricted stock units that upon vesting are settled on a one-for-one basis in shares of Class A common stock, vesting in full on February 5, 2028. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 16:15 UTC |
Morris David KDirector · See Remarks
|
GrantClass A Common Stock | 10,385 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-016284 · ownership.xml · nonDerivative · entry 1 Morris David K · CIK 0002037977 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,385 F1 · shares: Consists of restricted stock units that upon vesting are settled on a one-for-one basis in shares of Class A common stock, vesting in full on February 5, 2028. Read SEC document |
| November 19, 2024 Filed Nov 20, 2024 21:05 UTC |
COSLER STEVEN DDirector
|
PurchaseClass A Common Stock | 7,000 | $21.22 | $148,540.00 |
DisclosureSEC source: 0000950170-24-129229 · ownership.xml · nonDerivative · entry 1 COSLER STEVEN D · CIK 0001187946 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,713 F1 · shares: The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $20.81 to $21.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 18:42 UTC |
BINDLEY WILLIAM EDirector
|
GrantClass B Common Stock · Derivative | 24,400,702 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-111018 · ownership.xml · derivative · entry 1 BINDLEY WILLIAM E · CIK 0000903539 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Bindley Capital Partners I, LLC Disclosed balance after: 24,400,702 Underlying: Class A Common Stock · 24,400,702 shares Expires not disclosed F1 · security: Represents shares of Class B common stock issued pursuant to the Agreement and Plan of Merger, dated as of September 27, 2024 (the "Merger Agreement"), by and among Guardian Pharmacy Services, Inc. (the "Issuer"), Guardian Merger Corp., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Guardian Pharmacy, LLC, providing for the merger of Merger Sub with and into Guardian Pharmacy, LLC. As a result of the merger and pursuant to the Merger Agreement, each issued and outstanding common unit of Guardian Pharmacy, LLC (other than common units held by Guardian Investor, Inc.) was converted into one share of Class B common stock and the right to receive $1.02 in cash. The shares of Class B common stock issued will automatically convert into shares of Class A common stock on a one-for-one basis in four equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. F1 · derivative.exercise_price: Represents shares of Class B common stock issued pursuant to the Agreement and Plan of Merger, dated as of September 27, 2024 (the "Merger Agreement"), by and among Guardian Pharmacy Services, Inc. (the "Issuer"), Guardian Merger Corp., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Guardian Pharmacy, LLC, providing for the merger of Merger Sub with and into Guardian Pharmacy, LLC. As a result of the merger and pursuant to the Merger Agreement, each issued and outstanding common unit of Guardian Pharmacy, LLC (other than common units held by Guardian Investor, Inc.) was converted into one share of Class B common stock and the right to receive $1.02 in cash. The shares of Class B common stock issued will automatically convert into shares of Class A common stock on a one-for-one basis in four equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. F1 · price: Represents shares of Class B common stock issued pursuant to the Agreement and Plan of Merger, dated as of September 27, 2024 (the "Merger Agreement"), by and among Guardian Pharmacy Services, Inc. (the "Issuer"), Guardian Merger Corp., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Guardian Pharmacy, LLC, providing for the merger of Merger Sub with and into Guardian Pharmacy, LLC. As a result of the merger and pursuant to the Merger Agreement, each issued and outstanding common unit of Guardian Pharmacy, LLC (other than common units held by Guardian Investor, Inc.) was converted into one share of Class B common stock and the right to receive $1.02 in cash. The shares of Class B common stock issued will automatically convert into shares of Class A common stock on a one-for-one basis in four equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. F1 · derivative.exercise_date: Represents shares of Class B common stock issued pursuant to the Agreement and Plan of Merger, dated as of September 27, 2024 (the "Merger Agreement"), by and among Guardian Pharmacy Services, Inc. (the "Issuer"), Guardian Merger Corp., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Guardian Pharmacy, LLC, providing for the merger of Merger Sub with and into Guardian Pharmacy, LLC. As a result of the merger and pursuant to the Merger Agreement, each issued and outstanding common unit of Guardian Pharmacy, LLC (other than common units held by Guardian Investor, Inc.) was converted into one share of Class B common stock and the right to receive $1.02 in cash. The shares of Class B common stock issued will automatically convert into shares of Class A common stock on a one-for-one basis in four equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. F1 · derivative.expiration_date: Represents shares of Class B common stock issued pursuant to the Agreement and Plan of Merger, dated as of September 27, 2024 (the "Merger Agreement"), by and among Guardian Pharmacy Services, Inc. (the "Issuer"), Guardian Merger Corp., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Guardian Pharmacy, LLC, providing for the merger of Merger Sub with and into Guardian Pharmacy, LLC. As a result of the merger and pursuant to the Merger Agreement, each issued and outstanding common unit of Guardian Pharmacy, LLC (other than common units held by Guardian Investor, Inc.) was converted into one share of Class B common stock and the right to receive $1.02 in cash. The shares of Class B common stock issued will automatically convert into shares of Class A common stock on a one-for-one basis in four equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 21:43 UTC |
LEWIS RANDALL JDirector
|
GrantClass A Common Stock | 3,571 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-110981 · ownership.xml · nonDerivative · entry 2 LEWIS RANDALL J · CIK 0001123485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,142 F2 · shares: Represents restricted stock units payable solely in shares of Class A common stock of the Issuer. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 21:43 UTC |
LEWIS RANDALL JDirector
|
PurchaseClass A Common Stock | 3,571 | $14.00 | $49,994.00 |
DisclosureSEC source: 0000950170-24-110981 · ownership.xml · nonDerivative · entry 1 LEWIS RANDALL J · CIK 0001123485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,571 F1 · shares: Represents shares purchased pursuant to a directed share purchase program in connection with the Issuer's initial public offering. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 17:46 UTC |
Forbes KendallSee Remarks
|
GrantClass B Common Stock · Derivative | 2,434,280 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-110986 · ownership.xml · derivative · entry 1 Forbes Kendall · CIK 0002038507 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,434,280 Underlying: Class A Common Stock · 2,434,280 shares Expires not disclosed F1 · security: Represents shares of Class B common stock issued pursuant to the Agreement and Plan of Merger, dated as of September 27, 2024 (the "Merger Agreement"), by and among Guardian Pharmacy Services, Inc. (the "Issuer"), Guardian Merger Corp., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Guardian Pharmacy, LLC, providing for the merger of Merger Sub with and into Guardian Pharmacy, LLC. As a result of the merger and pursuant to the Merger Agreement, each issued and outstanding common unit of Guardian Pharmacy, LLC (other than common units held by Guardian Investor, Inc.) was converted into one share of Class B common stock and the right to receive $1.02 in cash. The shares of Class B common stock issued will automatically convert into shares of Class A common stock on a one-for-one basis in four equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. F1 · derivative.exercise_price: Represents shares of Class B common stock issued pursuant to the Agreement and Plan of Merger, dated as of September 27, 2024 (the "Merger Agreement"), by and among Guardian Pharmacy Services, Inc. (the "Issuer"), Guardian Merger Corp., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Guardian Pharmacy, LLC, providing for the merger of Merger Sub with and into Guardian Pharmacy, LLC. As a result of the merger and pursuant to the Merger Agreement, each issued and outstanding common unit of Guardian Pharmacy, LLC (other than common units held by Guardian Investor, Inc.) was converted into one share of Class B common stock and the right to receive $1.02 in cash. The shares of Class B common stock issued will automatically convert into shares of Class A common stock on a one-for-one basis in four equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. F1 · price: Represents shares of Class B common stock issued pursuant to the Agreement and Plan of Merger, dated as of September 27, 2024 (the "Merger Agreement"), by and among Guardian Pharmacy Services, Inc. (the "Issuer"), Guardian Merger Corp., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Guardian Pharmacy, LLC, providing for the merger of Merger Sub with and into Guardian Pharmacy, LLC. As a result of the merger and pursuant to the Merger Agreement, each issued and outstanding common unit of Guardian Pharmacy, LLC (other than common units held by Guardian Investor, Inc.) was converted into one share of Class B common stock and the right to receive $1.02 in cash. The shares of Class B common stock issued will automatically convert into shares of Class A common stock on a one-for-one basis in four equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. F1 · derivative.exercise_date: Represents shares of Class B common stock issued pursuant to the Agreement and Plan of Merger, dated as of September 27, 2024 (the "Merger Agreement"), by and among Guardian Pharmacy Services, Inc. (the "Issuer"), Guardian Merger Corp., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Guardian Pharmacy, LLC, providing for the merger of Merger Sub with and into Guardian Pharmacy, LLC. As a result of the merger and pursuant to the Merger Agreement, each issued and outstanding common unit of Guardian Pharmacy, LLC (other than common units held by Guardian Investor, Inc.) was converted into one share of Class B common stock and the right to receive $1.02 in cash. The shares of Class B common stock issued will automatically convert into shares of Class A common stock on a one-for-one basis in four equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. F1 · derivative.expiration_date: Represents shares of Class B common stock issued pursuant to the Agreement and Plan of Merger, dated as of September 27, 2024 (the "Merger Agreement"), by and among Guardian Pharmacy Services, Inc. (the "Issuer"), Guardian Merger Corp., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Guardian Pharmacy, LLC, providing for the merger of Merger Sub with and into Guardian Pharmacy, LLC. As a result of the merger and pursuant to the Merger Agreement, each issued and outstanding common unit of Guardian Pharmacy, LLC (other than common units held by Guardian Investor, Inc.) was converted into one share of Class B common stock and the right to receive $1.02 in cash. The shares of Class B common stock issued will automatically convert into shares of Class A common stock on a one-for-one basis in four equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 17:50 UTC |
Burke FredDirector · See Remarks
|
GrantClass B Common Stock · Derivative | 5,195,303 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-111000 · ownership.xml · derivative · entry 1 Burke Fred · CIK 0002037972 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,195,303 Underlying: Class A Common Stock · 5,195,303 shares Expires not disclosed F1 · security: Represents shares of Class B common stock issued pursuant to the Agreement and Plan of Merger, dated as of September 27, 2024 (the "Merger Agreement"), by and among Guardian Pharmacy Services, Inc. (the "Issuer"), Guardian Merger Corp., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Guardian Pharmacy, LLC, providing for the merger of Merger Sub with and into Guardian Pharmacy, LLC. As a result of the merger and pursuant to the Merger Agreement, each issued and outstanding common unit of Guardian Pharmacy, LLC (other than common units held by Guardian Investor, Inc.) was converted into one share of Class B common stock and the right to receive $1.02 in cash. The shares of Class B common stock issued will automatically convert into shares of Class A common stock on a one-for-one basis in four equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. F1 · derivative.exercise_price: Represents shares of Class B common stock issued pursuant to the Agreement and Plan of Merger, dated as of September 27, 2024 (the "Merger Agreement"), by and among Guardian Pharmacy Services, Inc. (the "Issuer"), Guardian Merger Corp., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Guardian Pharmacy, LLC, providing for the merger of Merger Sub with and into Guardian Pharmacy, LLC. As a result of the merger and pursuant to the Merger Agreement, each issued and outstanding common unit of Guardian Pharmacy, LLC (other than common units held by Guardian Investor, Inc.) was converted into one share of Class B common stock and the right to receive $1.02 in cash. The shares of Class B common stock issued will automatically convert into shares of Class A common stock on a one-for-one basis in four equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. F1 · price: Represents shares of Class B common stock issued pursuant to the Agreement and Plan of Merger, dated as of September 27, 2024 (the "Merger Agreement"), by and among Guardian Pharmacy Services, Inc. (the "Issuer"), Guardian Merger Corp., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Guardian Pharmacy, LLC, providing for the merger of Merger Sub with and into Guardian Pharmacy, LLC. As a result of the merger and pursuant to the Merger Agreement, each issued and outstanding common unit of Guardian Pharmacy, LLC (other than common units held by Guardian Investor, Inc.) was converted into one share of Class B common stock and the right to receive $1.02 in cash. The shares of Class B common stock issued will automatically convert into shares of Class A common stock on a one-for-one basis in four equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. F1 · derivative.exercise_date: Represents shares of Class B common stock issued pursuant to the Agreement and Plan of Merger, dated as of September 27, 2024 (the "Merger Agreement"), by and among Guardian Pharmacy Services, Inc. (the "Issuer"), Guardian Merger Corp., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Guardian Pharmacy, LLC, providing for the merger of Merger Sub with and into Guardian Pharmacy, LLC. As a result of the merger and pursuant to the Merger Agreement, each issued and outstanding common unit of Guardian Pharmacy, LLC (other than common units held by Guardian Investor, Inc.) was converted into one share of Class B common stock and the right to receive $1.02 in cash. The shares of Class B common stock issued will automatically convert into shares of Class A common stock on a one-for-one basis in four equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. F1 · derivative.expiration_date: Represents shares of Class B common stock issued pursuant to the Agreement and Plan of Merger, dated as of September 27, 2024 (the "Merger Agreement"), by and among Guardian Pharmacy Services, Inc. (the "Issuer"), Guardian Merger Corp., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Guardian Pharmacy, LLC, providing for the merger of Merger Sub with and into Guardian Pharmacy, LLC. As a result of the merger and pursuant to the Merger Agreement, each issued and outstanding common unit of Guardian Pharmacy, LLC (other than common units held by Guardian Investor, Inc.) was converted into one share of Class B common stock and the right to receive $1.02 in cash. The shares of Class B common stock issued will automatically convert into shares of Class A common stock on a one-for-one basis in four equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 17:53 UTC |
Morris David KDirector · See Remarks
|
GrantClass B Common Stock · Derivative | 2,567,477 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-111004 · ownership.xml · derivative · entry 1 Morris David K · CIK 0002037977 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,567,477 Underlying: Class A Common Stock · 2,567,477 shares Expires not disclosed F1 · security: Represents shares of Class B common stock issued pursuant to the Agreement and Plan of Merger, dated as of September 27, 2024 (the "Merger Agreement"), by and among Guardian Pharmacy Services, Inc. (the "Issuer"), Guardian Merger Corp., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Guardian Pharmacy, LLC, providing for the merger of Merger Sub with and into Guardian Pharmacy, LLC. As a result of the merger and pursuant to the Merger Agreement, each issued and outstanding common unit of Guardian Pharmacy, LLC (other than common units held by Guardian Investor, Inc.) was converted into one share of Class B common stock and the right to receive $1.02 in cash. The shares of Class B common stock issued will automatically convert into shares of Class A common stock on a one-for-one basis in four equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. F1 · derivative.exercise_price: Represents shares of Class B common stock issued pursuant to the Agreement and Plan of Merger, dated as of September 27, 2024 (the "Merger Agreement"), by and among Guardian Pharmacy Services, Inc. (the "Issuer"), Guardian Merger Corp., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Guardian Pharmacy, LLC, providing for the merger of Merger Sub with and into Guardian Pharmacy, LLC. As a result of the merger and pursuant to the Merger Agreement, each issued and outstanding common unit of Guardian Pharmacy, LLC (other than common units held by Guardian Investor, Inc.) was converted into one share of Class B common stock and the right to receive $1.02 in cash. The shares of Class B common stock issued will automatically convert into shares of Class A common stock on a one-for-one basis in four equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. F1 · price: Represents shares of Class B common stock issued pursuant to the Agreement and Plan of Merger, dated as of September 27, 2024 (the "Merger Agreement"), by and among Guardian Pharmacy Services, Inc. (the "Issuer"), Guardian Merger Corp., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Guardian Pharmacy, LLC, providing for the merger of Merger Sub with and into Guardian Pharmacy, LLC. As a result of the merger and pursuant to the Merger Agreement, each issued and outstanding common unit of Guardian Pharmacy, LLC (other than common units held by Guardian Investor, Inc.) was converted into one share of Class B common stock and the right to receive $1.02 in cash. The shares of Class B common stock issued will automatically convert into shares of Class A common stock on a one-for-one basis in four equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. F1 · derivative.exercise_date: Represents shares of Class B common stock issued pursuant to the Agreement and Plan of Merger, dated as of September 27, 2024 (the "Merger Agreement"), by and among Guardian Pharmacy Services, Inc. (the "Issuer"), Guardian Merger Corp., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Guardian Pharmacy, LLC, providing for the merger of Merger Sub with and into Guardian Pharmacy, LLC. As a result of the merger and pursuant to the Merger Agreement, each issued and outstanding common unit of Guardian Pharmacy, LLC (other than common units held by Guardian Investor, Inc.) was converted into one share of Class B common stock and the right to receive $1.02 in cash. The shares of Class B common stock issued will automatically convert into shares of Class A common stock on a one-for-one basis in four equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. F1 · derivative.expiration_date: Represents shares of Class B common stock issued pursuant to the Agreement and Plan of Merger, dated as of September 27, 2024 (the "Merger Agreement"), by and among Guardian Pharmacy Services, Inc. (the "Issuer"), Guardian Merger Corp., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Guardian Pharmacy, LLC, providing for the merger of Merger Sub with and into Guardian Pharmacy, LLC. As a result of the merger and pursuant to the Merger Agreement, each issued and outstanding common unit of Guardian Pharmacy, LLC (other than common units held by Guardian Investor, Inc.) was converted into one share of Class B common stock and the right to receive $1.02 in cash. The shares of Class B common stock issued will automatically convert into shares of Class A common stock on a one-for-one basis in four equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 17:49 UTC |
Ackerman JohnDirector
|
GrantClass B Common Stock · Derivative | 1,884,228 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-110998 · ownership.xml · derivative · entry 2 Ackerman John · CIK 0002037898 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Cardinal Equity Fund LP Disclosed balance after: 1,884,228 Underlying: Class A Common Stock · 1,884,228 shares Expires not disclosed F1 · security: Represents shares of Class B common stock issued pursuant to the Agreement and Plan of Merger, dated as of September 27, 2024 (the "Merger Agreement"), by and among Guardian Pharmacy Services, Inc. (the "Issuer"), Guardian Merger Corp., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Guardian Pharmacy, LLC, providing for the merger of Merger Sub with and into Guardian Pharmacy, LLC. As a result of the merger and pursuant to the Merger Agreement, each issued and outstanding common unit of Guardian Pharmacy, LLC (other than common units held by Guardian Investor, Inc.) was converted into one share of Class B common stock and the right to receive $1.02 in cash. The shares of Class B common stock issued will automatically convert into shares of Class A common stock on a one-for-one basis in four equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. F1 · derivative.exercise_price: Represents shares of Class B common stock issued pursuant to the Agreement and Plan of Merger, dated as of September 27, 2024 (the "Merger Agreement"), by and among Guardian Pharmacy Services, Inc. (the "Issuer"), Guardian Merger Corp., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Guardian Pharmacy, LLC, providing for the merger of Merger Sub with and into Guardian Pharmacy, LLC. As a result of the merger and pursuant to the Merger Agreement, each issued and outstanding common unit of Guardian Pharmacy, LLC (other than common units held by Guardian Investor, Inc.) was converted into one share of Class B common stock and the right to receive $1.02 in cash. The shares of Class B common stock issued will automatically convert into shares of Class A common stock on a one-for-one basis in four equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. F1 · price: Represents shares of Class B common stock issued pursuant to the Agreement and Plan of Merger, dated as of September 27, 2024 (the "Merger Agreement"), by and among Guardian Pharmacy Services, Inc. (the "Issuer"), Guardian Merger Corp., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Guardian Pharmacy, LLC, providing for the merger of Merger Sub with and into Guardian Pharmacy, LLC. As a result of the merger and pursuant to the Merger Agreement, each issued and outstanding common unit of Guardian Pharmacy, LLC (other than common units held by Guardian Investor, Inc.) was converted into one share of Class B common stock and the right to receive $1.02 in cash. The shares of Class B common stock issued will automatically convert into shares of Class A common stock on a one-for-one basis in four equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. F1 · derivative.exercise_date: Represents shares of Class B common stock issued pursuant to the Agreement and Plan of Merger, dated as of September 27, 2024 (the "Merger Agreement"), by and among Guardian Pharmacy Services, Inc. (the "Issuer"), Guardian Merger Corp., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Guardian Pharmacy, LLC, providing for the merger of Merger Sub with and into Guardian Pharmacy, LLC. As a result of the merger and pursuant to the Merger Agreement, each issued and outstanding common unit of Guardian Pharmacy, LLC (other than common units held by Guardian Investor, Inc.) was converted into one share of Class B common stock and the right to receive $1.02 in cash. The shares of Class B common stock issued will automatically convert into shares of Class A common stock on a one-for-one basis in four equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. F1 · derivative.expiration_date: Represents shares of Class B common stock issued pursuant to the Agreement and Plan of Merger, dated as of September 27, 2024 (the "Merger Agreement"), by and among Guardian Pharmacy Services, Inc. (the "Issuer"), Guardian Merger Corp., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Guardian Pharmacy, LLC, providing for the merger of Merger Sub with and into Guardian Pharmacy, LLC. As a result of the merger and pursuant to the Merger Agreement, each issued and outstanding common unit of Guardian Pharmacy, LLC (other than common units held by Guardian Investor, Inc.) was converted into one share of Class B common stock and the right to receive $1.02 in cash. The shares of Class B common stock issued will automatically convert into shares of Class A common stock on a one-for-one basis in four equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 17:49 UTC |
Ackerman JohnDirector
|
GrantClass B Common Stock · Derivative | 5,655,758 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-110998 · ownership.xml · derivative · entry 1 Ackerman John · CIK 0002037898 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Pharmacy Investors, LLC Disclosed balance after: 5,655,758 Underlying: Class A Common Stock · 5,655,758 shares Expires not disclosed F1 · security: Represents shares of Class B common stock issued pursuant to the Agreement and Plan of Merger, dated as of September 27, 2024 (the "Merger Agreement"), by and among Guardian Pharmacy Services, Inc. (the "Issuer"), Guardian Merger Corp., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Guardian Pharmacy, LLC, providing for the merger of Merger Sub with and into Guardian Pharmacy, LLC. As a result of the merger and pursuant to the Merger Agreement, each issued and outstanding common unit of Guardian Pharmacy, LLC (other than common units held by Guardian Investor, Inc.) was converted into one share of Class B common stock and the right to receive $1.02 in cash. The shares of Class B common stock issued will automatically convert into shares of Class A common stock on a one-for-one basis in four equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. F1 · derivative.exercise_price: Represents shares of Class B common stock issued pursuant to the Agreement and Plan of Merger, dated as of September 27, 2024 (the "Merger Agreement"), by and among Guardian Pharmacy Services, Inc. (the "Issuer"), Guardian Merger Corp., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Guardian Pharmacy, LLC, providing for the merger of Merger Sub with and into Guardian Pharmacy, LLC. As a result of the merger and pursuant to the Merger Agreement, each issued and outstanding common unit of Guardian Pharmacy, LLC (other than common units held by Guardian Investor, Inc.) was converted into one share of Class B common stock and the right to receive $1.02 in cash. The shares of Class B common stock issued will automatically convert into shares of Class A common stock on a one-for-one basis in four equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. F1 · price: Represents shares of Class B common stock issued pursuant to the Agreement and Plan of Merger, dated as of September 27, 2024 (the "Merger Agreement"), by and among Guardian Pharmacy Services, Inc. (the "Issuer"), Guardian Merger Corp., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Guardian Pharmacy, LLC, providing for the merger of Merger Sub with and into Guardian Pharmacy, LLC. As a result of the merger and pursuant to the Merger Agreement, each issued and outstanding common unit of Guardian Pharmacy, LLC (other than common units held by Guardian Investor, Inc.) was converted into one share of Class B common stock and the right to receive $1.02 in cash. The shares of Class B common stock issued will automatically convert into shares of Class A common stock on a one-for-one basis in four equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. F1 · derivative.exercise_date: Represents shares of Class B common stock issued pursuant to the Agreement and Plan of Merger, dated as of September 27, 2024 (the "Merger Agreement"), by and among Guardian Pharmacy Services, Inc. (the "Issuer"), Guardian Merger Corp., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Guardian Pharmacy, LLC, providing for the merger of Merger Sub with and into Guardian Pharmacy, LLC. As a result of the merger and pursuant to the Merger Agreement, each issued and outstanding common unit of Guardian Pharmacy, LLC (other than common units held by Guardian Investor, Inc.) was converted into one share of Class B common stock and the right to receive $1.02 in cash. The shares of Class B common stock issued will automatically convert into shares of Class A common stock on a one-for-one basis in four equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. F1 · derivative.expiration_date: Represents shares of Class B common stock issued pursuant to the Agreement and Plan of Merger, dated as of September 27, 2024 (the "Merger Agreement"), by and among Guardian Pharmacy Services, Inc. (the "Issuer"), Guardian Merger Corp., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Guardian Pharmacy, LLC, providing for the merger of Merger Sub with and into Guardian Pharmacy, LLC. As a result of the merger and pursuant to the Merger Agreement, each issued and outstanding common unit of Guardian Pharmacy, LLC (other than common units held by Guardian Investor, Inc.) was converted into one share of Class B common stock and the right to receive $1.02 in cash. The shares of Class B common stock issued will automatically convert into shares of Class A common stock on a one-for-one basis in four equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 17:48 UTC |
Salentine Thomas J JrDirector
|
GrantClass B Common Stock · Derivative | 24,400,702 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-110997 · ownership.xml · derivative · entry 2 Salentine Thomas J Jr · CIK 0002037899 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Bindley Capital Partners I, LLC Disclosed balance after: 24,400,702 Underlying: Class A Common Stock · 24,400,702 shares Expires not disclosed F2 · security: Represents shares of Class B common stock issued pursuant to the Agreement and Plan of Merger, dated as of September 27, 2024 (the "Merger Agreement"), by and among Guardian Pharmacy Services, Inc. (the "Issuer"), Guardian Merger Corp., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Guardian Pharmacy, LLC, providing for the merger of Merger Sub with and into Guardian Pharmacy, LLC. As a result of the merger and pursuant to the Merger Agreement, each issued and outstanding common unit of Guardian Pharmacy, LLC (other than common units held by Guardian Investor, Inc.) was converted into one share of Class B common stock and the right to receive $1.02 in cash. The shares of Class B common stock issued will automatically convert into shares of Class A common stock on a one-for-one basis in four equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. F2 · derivative.exercise_price: Represents shares of Class B common stock issued pursuant to the Agreement and Plan of Merger, dated as of September 27, 2024 (the "Merger Agreement"), by and among Guardian Pharmacy Services, Inc. (the "Issuer"), Guardian Merger Corp., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Guardian Pharmacy, LLC, providing for the merger of Merger Sub with and into Guardian Pharmacy, LLC. As a result of the merger and pursuant to the Merger Agreement, each issued and outstanding common unit of Guardian Pharmacy, LLC (other than common units held by Guardian Investor, Inc.) was converted into one share of Class B common stock and the right to receive $1.02 in cash. The shares of Class B common stock issued will automatically convert into shares of Class A common stock on a one-for-one basis in four equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. F2 · price: Represents shares of Class B common stock issued pursuant to the Agreement and Plan of Merger, dated as of September 27, 2024 (the "Merger Agreement"), by and among Guardian Pharmacy Services, Inc. (the "Issuer"), Guardian Merger Corp., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Guardian Pharmacy, LLC, providing for the merger of Merger Sub with and into Guardian Pharmacy, LLC. As a result of the merger and pursuant to the Merger Agreement, each issued and outstanding common unit of Guardian Pharmacy, LLC (other than common units held by Guardian Investor, Inc.) was converted into one share of Class B common stock and the right to receive $1.02 in cash. The shares of Class B common stock issued will automatically convert into shares of Class A common stock on a one-for-one basis in four equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. F2 · derivative.exercise_date: Represents shares of Class B common stock issued pursuant to the Agreement and Plan of Merger, dated as of September 27, 2024 (the "Merger Agreement"), by and among Guardian Pharmacy Services, Inc. (the "Issuer"), Guardian Merger Corp., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Guardian Pharmacy, LLC, providing for the merger of Merger Sub with and into Guardian Pharmacy, LLC. As a result of the merger and pursuant to the Merger Agreement, each issued and outstanding common unit of Guardian Pharmacy, LLC (other than common units held by Guardian Investor, Inc.) was converted into one share of Class B common stock and the right to receive $1.02 in cash. The shares of Class B common stock issued will automatically convert into shares of Class A common stock on a one-for-one basis in four equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. F2 · derivative.expiration_date: Represents shares of Class B common stock issued pursuant to the Agreement and Plan of Merger, dated as of September 27, 2024 (the "Merger Agreement"), by and among Guardian Pharmacy Services, Inc. (the "Issuer"), Guardian Merger Corp., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Guardian Pharmacy, LLC, providing for the merger of Merger Sub with and into Guardian Pharmacy, LLC. As a result of the merger and pursuant to the Merger Agreement, each issued and outstanding common unit of Guardian Pharmacy, LLC (other than common units held by Guardian Investor, Inc.) was converted into one share of Class B common stock and the right to receive $1.02 in cash. The shares of Class B common stock issued will automatically convert into shares of Class A common stock on a one-for-one basis in four equal tranches on each of March 28, 2025, September 27, 2025, March 28, 2026 and September 27, 2026. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 17:48 UTC |
Salentine Thomas J JrDirector
|
PurchaseClass A Common Stock | 35,714 | $14.00 | $499,996.00 |
DisclosureSEC source: 0000950170-24-110997 · ownership.xml · nonDerivative · entry 1 Salentine Thomas J Jr · CIK 0002037899 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,714 F1 · shares: Represents shares purchased pursuant to a directed share program in connection with the Issuer's initial public offering. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 21:43 UTC |
COSLER STEVEN DDirector
|
GrantClass A Common Stock | 3,571 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-110980 · ownership.xml · nonDerivative · entry 2 COSLER STEVEN D · CIK 0001187946 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,713 F2 · shares: Represents restricted stock units payable solely in shares of Class A common stock of the Issuer. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 21:43 UTC |
COSLER STEVEN DDirector
|
PurchaseClass A Common Stock | 7,142 | $14.00 | $99,988.00 |
DisclosureSEC source: 0000950170-24-110980 · ownership.xml · nonDerivative · entry 1 COSLER STEVEN D · CIK 0001187946 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,142 F1 · shares: Represents shares purchased pursuant to a directed share purchase program in connection with the Issuer's initial public offering. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 21:46 UTC |
Patchett Mary SueDirector
|
GrantClass A Common Stock | 3,571 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-110988 · ownership.xml · nonDerivative · entry 2 Patchett Mary Sue · CIK 0001568874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,142 F2 · shares: Represents restricted stock units payable solely in shares of Class A common stock of the Issuer. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 21:46 UTC |
Patchett Mary SueDirector
|
PurchaseClass A Common Stock | 3,571 | $14.00 | $49,994.00 |
DisclosureSEC source: 0000950170-24-110988 · ownership.xml · nonDerivative · entry 1 Patchett Mary Sue · CIK 0001568874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,571 F1 · shares: Represents shares purchased pursuant to a directed share purchase program in connection with the Issuer's initial public offering. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.